Targeted therapeutic approaches in chronic lymphocytic leukaemia (CLL)

AUS

$0

free

RACP

1 hr

Oncology

1 Credits

This course is expired! Browse All Courses
LEARN MORE

Course Description

This continuing medical education program is designed to provide haematologists with an up-to-date approach to the management of chronic lymphocytic leukaemia, with the aim of optimising outcomes for their patients.

The program has an emphasis on the role of emerging pharmacotherapies such as venetoclax on outcomes for patients with CLL, including the data on relapse rates and progression-free survival.

This program was sponsored by an independent educational grant provided by Abbvie.
Abbvie has had no input into its content. The interviews and opinions expressed do not necessarily reflect those of the sponsor.

Course Details

Expiry Date: 2023-03-02

Professions: Specialist

Faculty

Dr Mary Ann Anderson,
Walter and Eliza Hall Institute, Melbourne

Accreditation

This interactive online learning activity is valued at 1 Hour(s) of continuing education with RACP.

Learning Objective(s)

On completion of
this program, participants will be better able to:

  • Describe the underlying biology of chronic lymphocytic leukaemia (CLL) including its ability to avoid cell death (through apoptosis) by upregulation of BCL-2
  • Describe the impact of triggering apoptosis through BCL-2 inhibition on the clinical course of CLL
  • Identify the role of emerging pharmacotherapies such as venetoclax on outcomes for patients with CLL, including the data on relapse rates and progression-free survival
  • Compare the short-term and long-term toxicity profiles of venetoclax vs. chemoimmunotherapy and other agents
  • Counsel patients and colleagues on the features of venetoclax, such as mode of administration, toxicity profile, and identify a dosing schedule to maximise patient safety and drug efficacy.
This course is expired! Browse All Courses